A product and method of using albumin nanoparticles for treating multiple traumas by augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo for treating multiple traumas at the same time. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of multiple traumas. A function of the stem or precursor cells can be augmented or improved by the albumin spheres to stimulate mobilization toward the traumas, to ameliorate an inflammatory response of the subject by decreasing an amount of RANTES endothelial production on cytokines production, and/or to improve a secretion of fractalkine. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

The present invention is directed to compounds, methods for stabilizing thrombin activity with a thrombin binding oligonucleotide and to stabilized thrombin. The thrombin binding oligonucleotide is capable of inhibiting thrombin activity whereby the inhibition can be reversed with an antisense oligonucleotide.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated oxidized regenerated cellulose (ORC) fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

This disclosure relates to methods and materials for embolization of one or more blood vessels (e.g., one or more arteries). For example, biomaterial compositions (e.g., BEM compositions containing PRF and one or more nanoclay materials) for embolization of one or more blood vessels (e.g., one or more arteries) within a mammal (e.g., a human) are provided.

This disclosure relates to methods and materials for embolization of one or more blood vessels (e.g., one or more arteries). For example, biomaterial compositions (e.g., BEM compositions containing PRF and one or more nanoclay materials) for embolization of one or more blood vessels (e.g., one or more arteries) within a mammal (e.g., a human) are provided.

A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater and comprising at least one active ingredient.

A method of production of a tissue sealing patch is disclosed. The method comprises applying a vacuum to a heated work surface; applying a solution of a biocompatible polyurethane polymer to the work surface and spreading it over the work surface with a polymer blade; evaporating the solvent; heating the work surface above the softening temperature of the polymer; spreading powdered tissue sealant material over the polymer film; incorporating the tissue sealant material to a depth of 20-60 μm in the film by pressing on a release sheet placed over the powder and polymer film; removing the release sheet from the adhesive patch material; releasing the vacuum; cooling said work surface; and removing the adhesive patch material from said work surface. The biocompatible polymer preferably comprises PEG-caprolactone-lactic acid units connected by urethane linkages, the PEG having a molecular weight of 3000-3500 amu, and a CL:LA:PEG ratio of 34:2:1.

A method of production of a tissue sealing patch is disclosed. The method comprises applying a vacuum to a heated work surface; applying a solution of a biocompatible polyurethane polymer to the work surface and spreading it over the work surface with a polymer blade; evaporating the solvent; heating the work surface above the softening temperature of the polymer; spreading powdered tissue sealant material over the polymer film; incorporating the tissue sealant material to a depth of 20-60 μm in the film by pressing on a release sheet placed over the powder and polymer film; removing the release sheet from the adhesive patch material; releasing the vacuum; cooling said work surface; and removing the adhesive patch material from said work surface. The biocompatible polymer preferably comprises PEG-caprolactone-lactic acid units connected by urethane linkages, the PEG having a molecular weight of 3000-3500 amu, and a CL:LA:PEG ratio of 34:2:1.

This document provides methods and materials for performing retinal pigment epithelium transplantation. For example, methods and materials for using fibrin supports for retinal pigment epithelium transplantation are provided.

A formulation, or tissular adhesive, obtained from a platelet-rich blood composition and/or growth factors, and method for the preparation of this adhesive. The preparation method of the adhesive comprises the steps of raising the temperature of the initial blood composition and subsequently activating the composition. Among other advantages, the tissular adhesive is biocompatible and biodegradable, has desirable biological or medical properties provided by the presence of platelets or growth factors, and also has a high adhesiveness and an accelerated coagulation process.